SCHEMBL29615405

SCHEMBL29615405

N[C@@H](CCS)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.61
REN P00797 4/20 0.61
LMNA P02545 2/20 0.61
HSD17B10 Q99714 2/20 0.61
KDM4E B2RXH2 1/20 0.61
F2 P00734 1/20 0.61
LTA4H P09960 1/20 0.61
MAPT P10636 1/20 0.61
PEPD P12955 1/20 0.61
ALOX15 P16050 1/20 0.61
PTGS1 P23219 1/20 0.61
HTR2A P28223 1/20 0.61
PTGS2 P35354 1/20 0.61
HRH1 P35367 1/20 0.61
THPO P40225 1/20 0.61
PMP22 Q01453 1/20 0.61
ACE2 Q9BYF1 1/20 0.61
CYP2C19 P33261 1/20 0.50
DPP4 P27487 2/20 0.49
FAP Q12884 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11331490 0.89 ACE (0.68) ACERENLMNAHSD17B10KDM4E
SCHEMBL9052964 0.89 ACE (0.68) ACERENLMNAHSD17B10KDM4E
SCHEMBL3919811 0.89 ACE (0.68) ACERENLMNAHSD17B10KDM4E
SCHEMBL11563443 0.89 ACE (0.68) ACERENLMNAHSD17B10KDM4E
SCHEMBL31735178 0.88 DPP7 (0.62) ACERENLMNAHSD17B10KDM4E
SCHEMBL30314724 0.86 DPP4 (0.63) ACERENLMNAHSD17B10KDM4E
SCHEMBL10779357 0.86 ACE (0.71) ACERENLMNAHSD17B10KDM4E
SCHEMBL30052872 0.86 ACE (0.71) ACERENLMNAHSD17B10KDM4E
SCHEMBL10779361 0.86 ACE (0.71) ACERENLMNAHSD17B10KDM4E
SCHEMBL28827157 0.86 ACE (0.71) ACERENLMNAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053885-A1 PHARMACEUTICAL COMPOSITIONS RHYTHM PHARMACEUTICALS INC (US) 2026-02-26 US disclosed
US-12285460-B2 Pharmaceutical compositions RHYTHM PHARMACEUTICALS, INC. (US) 2025-04-29 US disclosed
US-20220160818-A1 PHARMACEUTICAL COMPOSITIONS RHYTHM PHARMACEUTICALS, INC. 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160818-A1 PHARMACEUTICAL COMPOSITIONS PCTP, SLC27A1, CETP ACE 3942/4885REN 2423/4885LMNA 3352/4885
US-12285460-B2 Pharmaceutical compositions PCTP, SLC27A1, CETP ACE 3942/4885REN 2423/4885LMNA 3352/4885
US-20260053885-A1 PHARMACEUTICAL COMPOSITIONS ARGLU1, FFAR3, ASNS ACE 3990/4885REN 2643/4885LMNA 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.